Cystatin C as a risk factor for outcomes in chronic kidney disease

被引:164
作者
Menon, Vandana
Shlipak, Michael G.
Wang, Xuelei
Coresh, Josef
Greene, Tom
Stevens, Lesley
Kusek, John W.
Beck, Gerald J.
Collins, Allan J.
Levey, Andrew S.
Sarnak, Mark J.
机构
[1] Tufts Univ, New England Med Ctr, Div Nephrol, Boston, MA 02111 USA
[2] Vet Affairs Med Ctr, San Francisco, CA 94121 USA
[3] Cleveland Clin Fdn, Cleveland, OH 44195 USA
[4] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA
[5] NIH, Bethesda, MD 20892 USA
[6] Univ Utah, Salt Lake City, UT USA
[7] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
关键词
D O I
10.7326/0003-4819-147-1-200707030-00004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: No study has compared cystatin C level, serum creatinine concentration, and estimated glomerular filtration rate (GFR) as risk factors for outcomes in chronic kidney disease (CKD), and none has compared measured GFR with CKD in any population. Objective: To compare cystatin C level with serum creatinine concentration and iothalamate GFR as risk factors for death and kidney failure. Design: Observational study using serum cystatin C assayed from baseline samples of the Modificztion of Diet in Renal Disease Study (1989-1993). Setting: 15 clinical centers in the United States that participated in the Modification of Diet in Renal Disease Study. Participants: 825 trial participants with stage 3 or 4 nondiabetic CKD who had measurements of serum cystatin C. Measurements: All-cause mortality, cardiovascular (CVD) mortality, and kidney failure until December 2000. Results: Mean cystatin C level, creatinine concentration, and GFR were 2.2 mg/L (SD, 0.7), 212.16 mu mol/L (SD, 88.4) (2.4 mg/dL [SD, 1.0]), and 33 mL/min per 1.73 m(2) (SD, 12), respectively. Median follow-up was 10 years. Twenty-five percent of patients (n = 203) died of any cause, 15% (n = 123) died of CVD, and 66% (n = 548) reached kidney failure. In multivariate-adjusted models, 1-SD decreases in 1/creatinine, GFR, and 1/cystatin C were associated with increased risks for all-cause mortality of 1.27 (95% Cl, 1.06 to 1.49), 1.27 (Cl, 1.08 to 1.49), and 1.41 (Cl, 1.18 to 1.67), respectively. For CVD mortality, the increased risks were 1.32 (Cl, 1.05 to 1.64), 1.28 (Cl, 1.04 to 1.59), and 1.64 (Cl, 1.28 to 2.08), respectively. For kidney failure, the increased risks were 2.81 (Cl, 2.48 to 3.18), 2.41 (Cl, 2.15 to 2.70), and 2.36 (Cl, 2.10 to 2.66), respectively. Limitation: The Modification of Diet in Renal Disease Study cohort may not be representative of all patients with nondiabetic CKD because participants were more likely to reach kidney failure than death in follow-up. Conclusion: The association of cystatin C level with all-cause and CVD mortality was as strong as or perhaps stronger than that of iothalamate GFR with these outcomes in stage 3 or 4 CKD.
引用
收藏
页码:19 / 27
页数:9
相关论文
共 43 条
[21]   A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation [J].
Levey, AS ;
Bosch, JP ;
Lewis, JB ;
Greene, T ;
Rogers, N ;
Roth, D .
ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :461-+
[22]   Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease [J].
Lloyd-Jones, Donald M. ;
Liu, Kiang ;
Tian, Lu ;
Greenland, Philip .
ANNALS OF INTERNAL MEDICINE, 2006, 145 (01) :35-42
[23]   Plasma cystatin-C and development of coronary heart disease: The PRIME Study [J].
Luc, G ;
Bard, JM ;
Lesueur, C ;
Arveiler, D ;
Evans, A ;
Amouyel, P ;
Ferrieres, J ;
Juhan-Vague, I ;
Fruchart, JC ;
Ducimetiere, P .
ATHEROSCLEROSIS, 2006, 185 (02) :375-380
[24]   Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community [J].
Manjunath, G ;
Tighiouart, H ;
Ibrahim, H ;
MacLeod, B ;
Salem, DN ;
Griffith, JL ;
Coresh, J ;
Levey, AS ;
Sarnak, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (01) :47-55
[25]  
Muntner P, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133745
[26]   SERUM CYSTATIN-C MEASURED BY AUTOMATED IMMUNOASSAY - A MORE SENSITIVE MARKER OF CHANGES IN GFR THAN SERUM CREATININE [J].
NEWMAN, DJ ;
THAKKAR, H ;
EDWARDS, RG ;
WILKIE, M ;
WHITE, T ;
GRUBB, AO ;
PRICE, CP .
KIDNEY INTERNATIONAL, 1995, 47 (01) :312-318
[27]   Cystatin C and incident peripheral arterial disease events in the elderly - Results from the cardiovascular health study [J].
O'Hare, AM ;
Newman, AB ;
Katz, R ;
Fried, LF ;
Stehman-Breen, CO ;
Seliger, SL ;
Siscovick, DS ;
Shlipak, MG .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (22) :2666-2670
[28]   Cystatin C improves the detection of mild renal dysfunction in older patients [J].
O'Riordan, SE ;
Webb, MC ;
Stowe, HJ ;
Simpson, DE ;
Kandarpa, M ;
Coakley, AJ ;
Newman, DJ ;
Saunders, JA ;
Lamb, EJ .
ANNALS OF CLINICAL BIOCHEMISTRY, 2003, 40 :648-655
[29]   Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes [J].
Oddoze, C ;
Morange, S ;
Portugal, H ;
Berland, Y ;
Dussol, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2001, 38 (02) :310-316
[30]   Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: Results of a 4-year follow-up study [J].
Perkins, BA ;
Nelson, RG ;
Ostrander, BEP ;
Blouch, KL ;
Krolewski, AS ;
Myers, BD ;
Warram, JH .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (05) :1404-1412